Prelude Capital Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Prelude Capital Management’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-136	Closed	-$7K	–	2228
2019 Q1	$7K	Sell	136 -153	-53%	-$6.81K	﹤0.01%	1603
2018 Q4	$12K	Buy	289 +153	+113%	+$7.88K	﹤0.01%	1345
2018 Q3	$9K	Sell	136 -3,271	-96%	-$248K	﹤0.01%	1490
2018 Q2	$258K	Buy	+3,407	New	+$214K	0.02%	701
2018 Q1	–	Sell	-3,407	Closed	-$182K	–	1763
2017 Q4	$182K	Sell	3,407 -611	-15%	-$34K	0.01%	634
2017 Q3	$240K	Buy	4,018 +1,400	+53%	+$84.7K	0.02%	584
2017 Q2	$207K	Buy	+2,618	New	+$214K	0.02%	568
2017 Q1	–	Sell	-3,260	Closed	-$259K	–	1836
2016 Q4	$259K	Buy	3,260 +2,830	+658%	+$206K	0.03%	483
2016 Q3	$30K	Buy	+430	New	+$23.8K	﹤0.01%	1226
2014 Q4	–	Sell	-100	Closed	-$1K	–	2203
2014 Q3	$1K	Buy	+100	New	+$1.24K	﹤0.01%	1828

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Prelude Capital Management's EGRX Position: Q2 2019 in Review

Prelude Capital Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2019, closing a stake of 136 shares — an estimated $7K sold.

Prelude Capital Management first reported a position in EGRX in Q3 2014 and held it in 10 quarters. The position peaked at $259K in Q4 2016. 180 funds tracked by Wall St. Rank hold EGRX as of Q2 2019.

Prelude Capital Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
Prelude Capital Management sold 136 Eagle Pharmaceuticals, Inc. shares in Q2 2019, an estimated $7K.
Prelude Capital Management first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2014 and held it in 10 quarters.
Prelude Capital Management's Eagle Pharmaceuticals, Inc. position peaked at $259K in Q4 2016.
180 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2019.

Based on Prelude Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.